Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Huot

Showing results (41-50 of 107) with videos related to

Pageof 11
Sort By:
Neuropharmacology|June 15, 2015
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Pharmacological Reviews|January 16, 2013
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Canadian Journal of Physiology and Pharmacology|February 5, 2020
Pharmacokinetic profile of the selective 5-HT<sub>3</sub> receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the ratCynthia Kwan, Dominique Bédard, Imane Frouni, et al.
Neuropharmacology|June 23, 2012
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Experimental Brain Research|March 25, 2024
[<sup>3</sup>H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brainImane Frouni, Esther Kim, Judy Shaqfah, et al.
European Journal of Pharmacology|September 4, 2021
Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmosetImane Frouni, Sébastien Belliveau, Shawn Maddaford, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 23, 2019
Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous doseFleur Gaudette, Dominique Bédard, Cynthia Kwan, et al.
Current Neurology and Neuroscience Reports|June 12, 2009
New insights into the organization of the basal gangliaJames B Koprich, Tom H Johnston, Philippe Huot, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 12, 2023
Pharmacokinetic profile of bitopertin, a selective GlyT<sub>1</sub> inhibitor, in the ratImane Frouni, Dominique Bédard, Élodie Bourgeois-Cayer, et al.
Journal of Chemical Neuroanatomy|August 21, 2007
L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeysPhilippe Huot, Martin Lévesque, Marc Morissette, et al.
Pageof 11

Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Neuropharmacology|June 15, 2015
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Pharmacological Reviews|January 16, 2013
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Canadian Journal of Physiology and Pharmacology|February 5, 2020
Pharmacokinetic profile of the selective 5-HT<sub>3</sub> receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the ratCynthia Kwan, Dominique Bédard, Imane Frouni, et al.
Neuropharmacology|June 23, 2012
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's diseasePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Experimental Brain Research|March 25, 2024
[<sup>3</sup>H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brainImane Frouni, Esther Kim, Judy Shaqfah, et al.
European Journal of Pharmacology|September 4, 2021
Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmosetImane Frouni, Sébastien Belliveau, Shawn Maddaford, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 23, 2019
Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous doseFleur Gaudette, Dominique Bédard, Cynthia Kwan, et al.
Current Neurology and Neuroscience Reports|June 12, 2009
New insights into the organization of the basal gangliaJames B Koprich, Tom H Johnston, Philippe Huot, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 12, 2023
Pharmacokinetic profile of bitopertin, a selective GlyT<sub>1</sub> inhibitor, in the ratImane Frouni, Dominique Bédard, Élodie Bourgeois-Cayer, et al.
Journal of Chemical Neuroanatomy|August 21, 2007
L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeysPhilippe Huot, Martin Lévesque, Marc Morissette, et al.
Pageof 11